Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc)(Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc))

概要

基本信息

药物类型

灭活疫苗、联合疫苗、预防性疫苗

+ [1]

别名

Boostrix、dTpa vaccine、Refortrix

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病其他疾病

在研适应症

白喉破伤风百日咳

非在研适应症-

原研机构

GSK Plc

在研机构

GlaxoSmithKline GmbH & Co. KGGlaxoSmithKline LLC

GSK Plc

+ [1]

非在研机构-

权益机构

GSK Plc

SK bioscience Co., Ltd.

最高研发阶段批准上市

首次获批日期

奥地利 (2000-10-03),

白喉破伤风百日咳

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

关联

49

项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的临床试验

NCT07097012

/ Recruiting临床4期IIT

Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy - A Pilot Feasibility Trial

The goal of this clinical trial is to learn if the RSV vaccine (protects against respiratory syncytial virus) and Tdap vaccine (protects against pertussis) are most effective in pregnant individuals when taken together at the same visit, or separately at different visits. This clinical trial will also learn about the safety and immune responses of these vaccines in pregnancy.
The Main question:
-Is it possible to run a successful trial that tests how safe and effective it is to give Tdap and RSV vaccines in pregnancy either at the same time or one after the other, at different visits?
The Secondary question:
-To determine how safe and how well the Tdap and RSV vaccines work when given in pregnancy either at the same time or one after the other, at different visits.
The Exploratory (optional participation) questions:
* To measure the levels of antibodies against whooping cough (pertussis) and RSV in mothers at 7 and 19 months after giving birth, depending on whether they got the vaccines at the same time or one after the other during pregnancy.
* To measure whooping cough antibody levels in the babies at 2, 7, and 19 months of age, whose mothers who received the vaccines in pregnancy.
* To measure the levels of RSV antibodies in the mothers' breast milk at 1 week, 2 weeks, 4 weeks, and 2 months after giving birth.
Participants will be randomly assigned to Group 1 (vaccines given at the same time, same visit) or Group 2 (vaccines given one after the other, at different visits).
There are 4 visits as part of the main study, and 6 additional visits as part of the optional study (exploratory questions).
Visit 1-2: Blood collection and vaccines administered Visit 3-4: Blood work (cord blood sample collection from infant, after delivery, if possible) Visit 5-8: Breast milk collection Visit 8-10: Blood collection (infant blood collection only at Visit 8).
Participants will be asked to keep a diary of symptoms throughout the study.

开始日期2025-10-16

申办/合作机构

Canadian Immunization Research Network

[+6]

NCT06494475

/ Not yet recruiting临床2/3期

A Randomised, Observer-Blind Trial to Evaluate the Immunogenicity, Safety, and Reactogenicity of a Group B Streptococcus Vaccine (GBS-NN/NN2) When 1 Dose is Administered Concomitantly With the Tdap Vaccine in Healthy-non Pregnant Women 18 to 49 Years of Age Compared to When Each Vaccine is Administered Alone

The main objectives of the study are to demonstrate the non-inferiority of the immune response induced by co administered GBS-NN/NN2 and tetanus, diphtheria, and acellular pertussis (Tdap) compared to the separate administration of GBS-NN/NN2 and Tdap, to evaluate the reactogenicity of GBS NN/NN2 when administered alone or in combination with Tdap, and to evaluate the safety of GBS-NN/NN2 when administered alone or in combination with Tdap in terms of serious adverse events (SAEs) and unsolicited adverse events (AEs).

开始日期2024-12-17

申办/合作机构

MinervaX ApS

NCT06015308

/ Completed临床2期

A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis

This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody responses, and the safety of amlitelimab concurrently administered with non-live vaccines in adult participants with moderate-to-severe atopic dermatitis (AD).
The purpose of this study is to compare the immune responses to concomitantly administered Boostrix (tetanus, diphtheria, and acellular pertussis [Tdap]) and Pneumovax 23 (PPSV) vaccines in adult participants with moderate-to-severe AD treated with amlitelimab versus placebo. The study will evaluate the percentage of participants achieving a positive anti-tetanus response at Week 16 (primary endpoint) and a positive anti-pneumococcal response at Week 16 (key secondary endpoint).
Study details include:
The study duration will be up to 36 weeks (for participants not entering the LTS17367 [RIVER-AD]).
The screening period will be 9 days to 4 weeks. The treatment duration will be up to 16 weeks. The post-treatment safety follow-up period will be16 weeks. The number of visits will be up to 7 (or 6 for those entering LTS17367 [RIVER-AD]).

开始日期2023-10-06

申办/合作机构

Sanofi

100 项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的临床结果

登录后查看更多信息

100 项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的转化医学

登录后查看更多信息

100 项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的专利（医药）

登录后查看更多信息

139

项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的文献（医药）

2026-01-01·LANCET INFECTIOUS DISEASES

Safety and immunogenicity of a conjugate vaccine candidate against Salmonella enterica serovars Typhi and Paratyphi A in healthy adults in Europe: a phase 1 randomised controlled trial

Article

作者: Berlanda Scorza, Francesco ; Nigro, Simona ; Rondini, Simona ; De Coster, Ilse ; Massai, Luisa ; Conti, Valentino ; Rossi, Omar ; La Gaetana, Rita ; Serry-Bangura, Alimamy ; Luna Cilio, Giulia ; AbdelGhany, Mohammad ; Fineschi, Chiara ; Withanage, Kanchanamala ; Carducci, Martina ; Van Damme, Pierre ; Tessitore, Pietro ; Nakakana, Usman N ; Micoli, Francesca ; Sarakinou, Eleanna ; Kumar Arora, Ashwani ; Marchetti, Elisa

BACKGROUND:

Enteric fever caused by Salmonella enterica serovars Typhi and Paratyphi A remains a major concern. No vaccines are licensed against Salmonella Paratyphi A. We aimed to assess the safety and immunogenicity of an investigational conjugate vaccine against Salmonella Typhi and Paratyphi A (Vi-CRM₁₉₇+O:2-CRM₁₉₇).

METHODS:

In this observer-masked, randomised, controlled, dose-escalation, single-centre, phase 1 trial done during Nov 28, 2022, to April 2, 2024, at the Centre for Evaluation of Vaccination in Belgium, healthy adults (aged 18-50 years) were randomly assigned (2:1 or 2:2:1 across different steps using sealed envelopes following a randomisation schedule generated by an independent statistician) to receive two intramuscular doses (on day 1 and day 169) of one of four Vi-CRM₁₉₇+O:2-CRM₁₉₇ formulations (low dose or full dose, with or without aluminium hydroxide) or a control vaccine (Vi capsular polysaccharide vaccine and diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine for first and second dose). The primary outcome was vaccine safety (solicited events during 7 days and unsolicited adverse events during 28 days after vaccination, serious adverse events [SAEs], and adverse events or SAEs leading to study withdrawal or withholding of further study intervention administration from day 1 to day 197, and deviations from normal or baseline laboratory test values 7 days after vaccination). Secondary outcomes included long-term vaccine safety (SAEs and adverse events or SAEs leading to study withdrawal from day 197 to day 337), and immunogenicity, including anti-Vi and anti-O:2 IgG antibody geometric mean concentrations and geometric mean ratios (GMRs) by ELISA, and seroresponses (percentages of participants with anti-Vi IgG concentrations ≥4·3 μg/mL and ≥2·0 μg/mL; ≥4-fold anti-O:2 IgG concentration increase from baseline) at day 1 (as applicable), day 29, day 169, day 176, and day 197. Safety analyses were done on the solicited safety set, unsolicited safety set, and the exposed set. The primary immunogenicity analysis was done on the per-protocol set defined by timepoint. The trial is registered with ClinicalTrials.gov (NCT05613205) and gsk-studyregister.com (205480), and is completed.

FINDINGS:

96 participants were randomly assigned, 12 to each low-dose group, 24 to each full-dose group, and 24 to the control group. The incidence of solicited administration-site events (mostly pain) ranged from six (50% [95% CI 21·1-78·9]) of 12 participants in the low-dose without aluminium hydroxide group to 23 (96% [78·9-99·9]) of 24 in the full-dose with aluminium hydroxide group, versus 22 (92% [73·0-99·0]) of 24 in the control group. Solicited systemic events (mostly fatigue, headache, and myalgia) ranged from eight (67% [34·9-90·1]) of 12 in the low-dose groups to 20 (83% [62·6-95·3]) of 24 in the full-dose with aluminium hydroxide group, versus 21 (88% [67·6-97·3]) of 24 in the control group. The incidence of unsolicited adverse events (mostly nasopharyngitis) ranged from seven (58% [27·7-84·8]) of 12 in the low-dose without aluminium hydroxide group to ten (83% [51·6-97·9]) of 12 in the low-dose with aluminium hydroxide group, versus 14 (58% [36·6-77·9]) of 24 in the control group. Most safety laboratory results were within reference ranges. No SAEs occurred. After dose 1 (ie, at day 29), full-dose without aluminium hydroxide and full-dose with aluminium hydroxide induced the highest anti-Vi IgG responses (GMR 53·01 [95% CI 31·94-87·99] and 31·55 [18·74-53·11], respectively) versus control (4·50 [2·93-6·90]). Full-dose without aluminium hydroxide and low-dose without aluminium hydroxide induced the highest anti-O:2 IgG responses after dose 1 (GMR 162·61 [91·17-290·04] and 114·19 [44·83-290·86], respectively), versus control (1·27 [1·02-1·60]). 89-100% and 82-100% of participants (lowest percentages for low-dose with aluminium hydroxide) had anti-Vi IgG ≥4·3 μg/mL at day 29 (in initially seronegative participants) and ≥4-fold anti-O:2 IgG increase from baseline, respectively, versus 13 (54% [95% CI 32·8-74·4]) and one (4% [0·1-21·1]) of 24 participants in the control group, respectively. The second dose did not boost the responses.

INTERPRETATION:

Vi-CRM₁₉₇+O:2-CRM₁₉₇ formulations did not raise safety concerns and showed immunogenicity with a single dose, supporting further clinical assessment of the full-dose without aluminium hydroxide in target populations (infants and older age groups) in endemic regions.

FUNDING:

Wellcome Trust.

2025-12-31·Human Vaccines & Immunotherapeutics

Economic evaluation of the second booster dose of diphtheria-tetanus-acellular pertussis vaccine for children aged 6 years in Zhejiang Province: A cost-utility analysis

Article

作者: Zheng, Shuhan ; Zhou, Yang ; Su, Ying ; He, Hanqing ; Zhu, Yao ; Luo, Feng ; Tang, Xuewen

Despite increasing pertussis breakthroughs and waning immunity, this study evaluates the cost-effectiveness of replacing the DT booster with DTaP in 6-year-olds in Zhejiang, China. While implemented in high-income regions, this strategy's cost-effectiveness remains unassessed in diverse Chinese settings. We address this gap using local data.Using surveillance data from the Zhejiang Provincial Center for Disease Control and Prevention, literature reviews, and a 10-year simulation timeframe, a decision tree-Markov model was constructed from a societal perspective. The study cohort was 6-year-old children in Zhejiang Province in 2022. Comprehensive evaluation indicators, including Incremental Cost Effectiveness Ratio (ICER) and Incremental Cost-Utility Ratio (ICUR), were used. Robustness was assessed via Deterministic Sensitivity Analysis (DSA) and Probabilistic Sensitivity Analysis (PSA). Simulating 10 years after implementing the DTaP strategy for 628,619 children in 2022, under lower background incidence, DTaP could prevent 1,886 pertussis cases, reduce costs by 1.7 billion CNY, and gain 0.09 QALYs (ICUR = 3,096.15 CNY/QALY). Under higher incidence, it could prevent 8,743 cases, reduce costs by 1.6 billion CNY, and gain 0.084 QALYs (ICUR = 3,081.86 CNY/QALY). Both ICUR values are significantly lower than Zhejiang's per capita GDP (118,496 CNY). Our findings indicate that administering a second booster dose of DTaP to 6-year-old children is cost-effective, particularly with high incidence of pertussis.

2025-05-01·PEDIATRIC INFECTIOUS DISEASE JOURNAL

Acellular Pertussis Vaccine Given in the Week After Birth Does Not Impair Antibody Responses to Later Childhood Doses

Article

作者: Marshall, Helen S. ; Richmond, Peter ; McAlister, Sonia M. ; McIntyre, Peter ; van den Biggelaar, Anita H.J. ; Wood, Nicholas ; Thornton, Ruth ; Nolan, Terry ; Cooper, Matthew N.

Background::

A birth acellular pertussis vaccine may be a valuable alternative for immunity against infant pertussis when a pregnancy pertussis vaccine has not been administered. We assessed whether a birth dose may impair immunoglobulin G (IgG) responses to childhood pertussis boosters.

Methods::

Children from our previous randomized controlled trial who received a monovalent 3-component aP and hepatitis B vaccine at birth (aP group) or hepatitis B only (control group) followed by Infanrix hexa at 2, 4 and 6 months of age were randomized to receive either high or low-dose diphtheria-tetanus acellular pertussis combination vaccine (DTPa—Infanrix/dTpa—Boostrix) at 18 months and 4 years of age. Serum DTPa-specific IgG was measured pre- and postboost at 18 months and 4 years to determine immunogenicity and potential hyporesponsiveness across vaccination schedules.

Results::

Children who received a neonatal aP dose had improved pertussis toxin-IgG persistence and enhanced postvaccination pertactin and filamentous hemagglutinin-IgG responses at 18 months. Hyporesponsiveness was not detected across the study period, and all schedules showed good immunogenicity to subsequent boosters. The high-dose DTPa vaccine consistently induced higher antibody titers than the low-dose dTpa vaccine. Either booster dose was able to bridge immunity between 6 months and 4 years.

Conclusions::

A birth dose of acellular pertussis vaccine does not impair antibody responses to booster doses of pertussis vaccines and may be an alternative for protection against early infant pertussis when pertussis booster has not been administered during pregnancy.

27

项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的新闻（医药）

2026-03-11

·EINPresswire

Whooping Cough Continues Wyoming Spread

March 11, 2026 Wyoming Department of Health (WDH) officials are concerned about the ongoing, active spread of pertussis (whooping cough) across the state. Kaylyn Friesen, vaccine-preventable disease epidemiologist with WDH, said there have been 26 confirmed pertussis cases in Wyoming so far this year. “While roughly two-thirds of the reported cases have been among Fremont County residents, pertussis has also been identified in other counties,” Friesen said. Friesen noted that 148 cases were reported in Wyoming in 2025, the highest since 1951. “We are continuing to see outbreaks and high monthly case counts,” Friesen said. Actual case numbers are likely higher because many illnesses are not recognized as pertussis, and others may not be reported. Pertussis typically begins with cold-like symptoms and perhaps a mild cough. Pertussis is often not suspected or diagnosed until a persistent cough with spasms develops after 1 to 2 weeks. Infants and children can cough violently and rapidly with a loud “whooping” sound. Dr. Alexia Harrist, state health officer with WDH, said, “One-third of infants less than 1 year of age who become ill with pertussis need to be hospitalized, and we know, in some cases, it can be deadly for these babies. Pertussis in the youngest babies can cause them to have pauses in breathing. Infants are simply more vulnerable and don’t yet have all the protection pertussis vaccines offer.” Harrist said the Tdap adolescent/adult pertussis booster vaccine is especially important for those spending time with new infants, such as parents, grandparents, and other people who take care of them. “Also, if you are pregnant or planning on becoming pregnant, you should talk to your doctor about a Tdap vaccine because that can also help protect newborns,” she said. Harrist recommends that all residents stay up to date with pertussis vaccines, as those who still become ill with pertussis after vaccination are less likely to have a severe experience. “In addition, people should consider seeing a medical professional for antibiotics if they have symptoms consistent with pertussis,” she said. More information about pertussis can be found online at https://health.wyo.gov/publichealth/infectious-disease-epidemiology-unit/disease/pertussis/ . Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

疫苗

2026-01-09

·drugs

Maternal Flu, Tdap Shots May Lower Rates of Infant Hospitalization, ED Visits

FRIDAY, Jan. 9, 2026 -- Maternal influenza and tetanus-diphtheria-acellular pertussis (Tdap) vaccinations are associated with a lower risk for influenza- and pertussis-related hospitalization or emergency department (ED) visits in infants younger than 6 months, according to a study published online Jan. 8 in JAMA Network Open . Gabriella Morabito, from the National Centre for Healthcare Research and Pharmacoepidemiology at the University of Milano-Bicocca Milan in Italy, and colleagues conducted a population-based cohort study using health care utilization databases from the Lombardy region of Italy to examine the association of maternal influenza and Tdap vaccinations with influenza- and pertussis-related hospitalizations and ED visits among infants aged younger than 6 months. A total of 53,448 pregnant individuals who received the Tdap vaccine and 5,347 who received the influenza vaccine were included in the study. Maternal vaccination coverage was 6.4 and 41.0 percent for influenza and Tdap, respectively. The researchers found that the risk for hospitalization or ED visits for influenza and pertussis was lower among infants born to mothers who received the influenza and Tdap vaccines (vaccine effectiveness, 69.7 and 88.6 percent, respectively). "These results support the current recommendations for administering these vaccines during pregnancy and highlight the urgent need to implement strategies aimed to increase their acceptance," the authors write. One author disclosed ties to the pharmaceutical industry. Abstract/Full Text

疫苗临床结果

2025-11-20

·drugs

Whooping Cough Surges Nationwide as Vaccinations Fall

THURSDAY, Nov. 20, 2025 — Whooping cough is making a major comeback in the United States, with sharp increases now seen in Texas, Florida, California, Oregon and many other places. Health officials say the latest rise in pertussis cases is being driven by falling vaccination rates, waning immunity and slower public health tracking systems. What's more, officials say, is that babies remain the most vulnerable. "Pertussis cases increase in a cyclical fashion driven by waning immunity," Dr. Demetre Daskalakis , former head of the U.S. Centers for Disease Control and Prevention's (CDC) immunization program, told CBS News . "But the size of the outbreak and the potential for severe outcomes in children who cannot be vaccinated can be mitigated by high coverage and good communication to folks at risk," he added. Before a vaccine was introduced in the early 1900s, whooping cough was one of the leading causes of childhood death in the United States. Today, routine vaccination starts at 2 months old and continues through adulthood with booster shots. But the pandemic brought a drop in vaccine uptake and nonmedical exemptions in some states have widened immunity gaps. Texas illustrates how quickly case numbers have grown. The state reported 1,928 cases in 2024. By October 2025, that number had already climbed past 3,500. National trends are just as shocking. In the first three months of 2025, the United States counted 6,600 pertussis cases, four times last year’s pace and 25 times the pace in 2023. Outbreaks in places like Louisiana, South Dakota and Idaho show the problem is not limited to just one region of the country. Texas recently made it easier for parents to claim exemptions by letting them download forms online, and Dallas County Health Director Dr. Phil Huang said he has already seen a drop in families coming in for routine shots. He also worries that some families, especially in Dallas County’s 40% Hispanic population, may be avoiding vaccinations because of immigration enforcement concerns. Another issue is that protection from the current “acellular” pertussis vaccine wears off over time, leaving many adults without strong immunity. This makes it easier for adults to unknowingly spread the illness to infants. Babies face the highest risk: about 1 in 5 infants with pertussis develop pneumonia , and about 1% die from the infection, according to the CDC. The CDC stresses that pregnant women should get a Tdap vaccine during every pregnancy so their newborns receive antibodies before birth. More cases are also being found because clinics now use modern PCR testing that checks for several respiratory infections at once, including pertussis. Even so, the number of infant hospitalizations shows that true transmission is increasing. Doctors usually treat pertussis with macrolide antibiotics, but resistant strains have been rising in other countries such as China and Peru, reports CBS News . Resistant cases remain rare in the United States, although officials caution that international travel could change that. Health experts say the best strategy now is early detection and vaccination. Clinicians are being urged to consider pertussis whenever a patient has a persistent cough, especially if the patient is an infant or a caregiver of a baby. Families are also encouraged to make sure children, teens and adults are up to date on their vaccines and to keep sick visitors away from newborns. Sources CBS News, Nov. 19, 2025

疫苗

100 项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07CA02	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
白喉	奥地利	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	比利时	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	保加利亚	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	克罗地亚	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	塞浦路斯	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	捷克	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	丹麦	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	爱沙尼亚	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	芬兰	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	法国	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	德国	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	希腊	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	匈牙利	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	冰岛	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	爱尔兰	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	意大利	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	拉脱维亚	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	立陶宛	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	卢森堡	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	马耳他	GlaxoSmithKline GmbH & Co. KG	2000-10-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05169905 (CTgov)	临床3期	呼吸道合胞体病毒感染	9	RSV MAT vaccine+dTpa vaccine (RSV_dTpa-P Group)	夢觸憲襯選窪選網餘衊 = 鑰鏇壓繭齋觸廠鏇廠糧積製鹽願範壓獵積遞觸 (選範顧夢願衊憲構鬱糧, 艱膚醖糧製窪壓繭鹹顧 ~ 淵鏇廠觸網觸願鹹網簾) 更多	-	2023-04-07
				RSV MAT vaccine+dTpa vaccine (RSV_dTpa-A Group)	夢觸憲襯選窪選網餘衊 = 蓋鹽選觸憲選鬱觸觸壓積製鹽願範壓獵積遞觸 (選範顧夢願衊憲構鬱糧, 憲鏇鹽獵鑰襯選選糧廠 ~ 選鬱壓鬱範膚醖憲願鬱) 更多
NCT03589768 (CTgov)	临床2期	白喉 \| 百日咳 \| 艰难梭菌结肠炎 ... 更多	399	BOOSTRIX (BOOSTRIX - Maternal)	廠觸獵鬱願鹽鏇鏇壓夢 = 窪獵憲憲壓窪鬱齋簾鏇壓遞襯糧築網淵夢醖遞 (夢築顧蓋遞齋膚願衊鏇, 廠蓋鏇願簾窪遞鹽齋鏇 ~ 艱製鑰積顧壓鹹壓鹹鬱) 更多	-	2023-01-20
				Td (Td - Maternal)	廠觸獵鬱願鹽鏇鏇壓夢 = 繭簾窪獵積願鬱憲遞網壓遞襯糧築網淵夢醖遞 (夢築顧蓋遞齋膚願衊鏇, 憲淵製齋獵顧鹽窪鑰網 ~ 積鑰鹹餘蓋膚鬱顧憲窪) 更多
NCT03311659 (CTgov)	临床3期	白喉 \| 百日咳 \| 破伤风	448	Boostrix	範鬱簾獵遞網遞簾顧壓 = 糧膚蓋獵憲衊網顧繭衊憲範憲網衊觸蓋廠選鹽 (繭醖獵廠憲獵網憲選淵, 淵廠顧築顧餘廠構遞顧 ~ 鏇願製壓製壓壓餘蓋壓) 更多	-	2019-10-23
NCT02377349 (CTgov)	临床4期	白喉 \| 百日咳 \| 破伤风	688	dTpa (dTpa Group - Mother)	壓鬱鏇繭淵糧獵憲艱糧(壓顧選製鏇簾願艱積鬱) = 衊廠鏇顧積簾觸憲齋觸膚顧廠窪網願鑰廠餘觸 (襯選願蓋構繭膚醖鑰齋, 膚觸選壓鏇鹹鏇構觸遞 ~ 選觸憲繭壓膚簾構鏇憲) 更多	-	2019-01-28
				placebo+Boostrix (Control Group - Mother)	壓鬱鏇繭淵糧獵憲艱糧(壓顧選製鏇簾願艱積鬱) = 膚構範廠鬱壓膚餘廠鏇膚顧廠窪網願鑰廠餘觸 (襯選願蓋構繭膚醖鑰齋, 簾鬱遞蓋淵餘夢鏇網憲 ~ 窪願壓餘齋遞膚壓鑰鑰) 更多
NCT00548171 (CTgov)	临床4期	白喉 \| 百日咳 \| 破伤风	203	Boostrix™ (Boostrix I Group)	膚糧鬱顧壓膚遞網範糧 = 窪襯繭選壓構鹽鹽襯鹽淵鏇鏇膚網鬱廠獵鏇壓 (願觸繭廠網鏇醖觸鬱獵, 顧願鑰鏇襯淵襯廠築鹹 ~ 鑰鹹壓鹽範襯醖願廠選) 更多	-	2019-01-15
				Boostrix™ (Boostrix II Group)	膚糧鬱顧壓膚遞網範糧 = 觸構衊蓋艱餘繭襯觸範淵鏇鏇膚網鬱廠獵鏇壓 (願觸繭廠網鏇醖觸鬱獵, 製餘壓齋範鹹鹹構艱糧 ~ 鏇憲廠襯獵製獵憲願網) 更多
NCT00385255 (CTgov)	临床3期	白喉 \| 百日咳 \| 破伤风	1,726	Fluarix®+Boostrix® (Boostrix+Fluarix Group)	鹽淵蓋遞繭鏇網繭繭蓋(鹽襯構獵憲鏇遞積選繭) = 網顧積醖廠顧繭網艱築選淵齋廠齋壓鹹衊顧壓 (蓋廠窪築襯餘獵積壓膚, 淵艱遞糧願製觸鬱醖製 ~ 襯鹹夢鏇蓋衊淵積範艱) 更多	-	2018-09-17
				Fluarix®+Boostrix® (Fluarix Boostrix Group)	鹽淵蓋遞繭鏇網繭繭蓋(鹽襯構獵憲鏇遞積選繭) = 簾淵鏇鏇窪壓艱鏇齋憲選淵齋廠齋壓鹹衊顧壓 (蓋廠窪築襯餘獵積壓膚, 鹽膚醖鬱窪窪鹽齋鏇觸 ~ 鹹淵襯獵夢遞鹽獵蓋醖) 更多
NCT00346073 (CTgov)	临床3期	白喉 \| 百日咳 \| 破伤风	2,337	Boostrix™ (Boostrix Group)	淵構鹹遞選構壓壓襯淵 = 衊醖觸鬱觸壓壓壓製積鏇鑰築艱範窪壓築憲夢 (窪壓鹽襯憲憲構艱鹹襯, 鑰廠範積窪製築遞製築 ~ 鹽糧糧糧積製築願繭鬱) 更多	-	2018-08-07
				ADACEL® (Adacel Group)	淵構鹹遞選構壓壓襯淵 = 鬱積餘選鹽選艱繭網鬱鏇鑰築艱範窪壓築憲夢 (窪壓鹽襯憲憲構艱鹹襯, 窪遞膚積積積鹹襯積鹹 ~ 膚選鑰獵選壓淵繭獵淵) 更多
NCT01755689 (Pubmed \| Vaccine) 人工标引	临床3期	脑膜炎球菌感染	1,300	MenACWY-TT+human papillomavirus 16/18 AS04-adjuvanted vaccine+tetanus-diphtheria-acellular pertussis vaccine	築獵齋餘獵遞遞艱鹽醖(顧窪膚夢構窪糧膚積製) = No safety concerns were identified 蓋艱範範構繭鏇鬱壓廠 (獵憲鹹醖蓋憲獵鏇齋衊 ) 更多	积极	2018-06-22
NCT01738477 (CTgov)	临床3期	白喉 \| 百日咳 \| 破伤风	165	Boostrix (Boostrix Group 1)	齋窪鬱蓋膚築憲廠鏇糧 = 淵蓋鹽願鏇憲網製餘鹹簾蓋願膚廠醖齋淵選齋 (衊製構獵顧鑰鑰構憲齋, 鏇齋艱壓艱願積製獵壓 ~ 築遞糧構艱鹽製鏇襯糧) 更多	-	2017-12-27
				Boostrix (Boostrix Group 2)	齋窪鬱蓋膚築憲廠鏇糧 = 襯鬱範淵鏇艱選窪網齋簾蓋願膚廠醖齋淵選齋 (衊製構獵顧鑰鑰構憲齋, 繭艱蓋糧壓獵衊鬱糧觸 ~ 願鹽鏇觸遞艱繭鹽衊網) 更多
NCT00282295 (CTgov)	临床4期	白喉 \| 脑膜炎球菌感染 \| 百日咳 ... 更多	1,344	Menactra™+Boostrix® (Boostrix + Menactra Group)	網選鏇遞蓋鬱憲積憲鹹 = 築鑰願範觸餘觸糧淵襯餘窪鬱鬱鹹憲蓋範衊簾 (齋範選製範壓憲窪鹽願, 鹹製夢鬱憲蓋鏇範顧築 ~ 鏇淵鹽齋獵鹹鏇鹽鑰範) 更多	-	2017-03-16
				Menactra™+Boostrix® (Boostrix-Menactra Group)	網選鏇遞蓋鬱憲積憲鹹 = 夢憲膚壓膚鹽構簾襯淵餘窪鬱鬱鹹憲蓋範衊簾 (齋範選製範壓憲窪鹽願, 蓋鏇壓齋餘繭鑰齋蓋鑰 ~ 鬱鬱蓋鬱衊鬱範鏇構築) 更多